Enterovirus 71 Human

1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Medigen Vaccine Biologics
2 programs
1
EV71 with adjuvant aluminium phosphatePhase 21 trial
EV71 vaccineN/AVaccine1 trial
Active Trials
NCT04072276CompletedEst. Dec 2021
NCT02200237CompletedEst. Aug 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Medigen Vaccine BiologicsEV71 with adjuvant aluminium phosphate
Medigen Vaccine BiologicsEV71 vaccine

Clinical Trials (2)

NCT02200237Medigen Vaccine BiologicsEV71 with adjuvant aluminium phosphate

A Clinical Study for Inactivated Vaccine Against EV71

Start: Sep 2014Est. completion: Aug 2017
Phase 2Completed

Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children

Start: Aug 2019Est. completion: Dec 2021
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Vaccine is the dominant modality (100% of programs)
1 companies competing in this space